Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | BACE1 | P56817 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14139761 | 0.95 | LCK (0.51) | LCKGSK3BBACE1PPARGPPARA | |
| SCHEMBL10069203 | 0.84 | MEN1 (0.40) | LCKPPARGNPC1RAB9ALMNA | |
| SCHEMBL13127037 | 0.83 | RELA (0.54) | NPC1RAB9ASMN1; SMN2CYP1A2CYP1A1 | |
| SCHEMBL10069727 | 0.80 | APP (0.52) | SMN1; SMN2HDAC6KDM4EMEN1KMT2A | |
| SCHEMBL13127036 | 0.80 | TRPA1 (0.49) | NPC1RAB9ASMN1; SMN2CYP1A2CYP1A1 | |
| SCHEMBL10069905 | 0.80 | LCK (0.56) | LCKGSK3BBACE1PPARGPPARA | |
| SCHEMBL13126944 | 0.79 | LCK (0.54) | LCKGSK3BBACE1PPARGPPARA | |
| SCHEMBL20024692 | 0.78 | LCK (0.77) | LCKGSK3BBACE1PPARGPPARA | |
| SCHEMBL14786203 | 0.78 | LCK (0.77) | LCKGSK3BBACE1PPARGPPARA | |
| SCHEMBL13822222 | 0.77 | PPARA (0.34) | PPARGPPARANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124626-B2 | Methods of treating inflammations and infections with pyridinium salts | MYCOSOL, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7820696-B2 | Compounds and methods for controlling fungi, bacteria and insects | MYCOSOL, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | KLEIN RICHARD B | 2010-10-21 | — | — | US | disclosed |
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | MYCOSOL, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7220761-B2 | Compounds and methods for controlling fungi, bacteria and insects | MYCOSOL, INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | BLVRB, PNPO, PLPBP | LCK 1734/4885GSK3B 2917/4885BACE1 3815/4885 |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | PNPO, PLPBP, TPMT | LCK 97/4885GSK3B 1989/4885BACE1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.